

Supplement Methods

Literature search and inclusion

Database search keywords for Generalized Anxiety Disorder (GAD) included: (“generalized anxiety disorder”, OR (“GAD”)) AND (“voxel-based morphometry”, OR (“VBM”), OR (“gray matter”)).

Database search keywords for Fear-related Anxiety Disorders (FAD) included: (“social anxiety disorder”, OR (“social phobia”), OR (“SAD”), OR (“specific phobia”), OR (“panic disorder”), OR (“Phobia”), OR (“agoraphobia”)) AND (“voxel-based morphometry”, OR (“VBM”), OR (“gray matter”)).

Database search keywords for Major Depressive Disorder (MDD) included: “Depression” AND (“voxel-based morphometry”, OR (“VBM”), OR (“gray matter”)). Broad search terms were used to prevent missing any relevant studies. Additionally, we inspected reference lists of relevant reviews and original studies to identify further eligible articles.

Key inclusion criteria were (1) neuroimaging case control design studies comparing brain structure between a group of patients with GAD, FAD or MDD with healthy controls (HC), and (2) whole-brain VBM between-group comparisons (including null findings) reported. Studies were excluded if they (1) were non-empirical studies (e.g., review, meta-analysis, meeting abstract); (2) were not published in English; (3) did not report direct comparison between a patient and healthy control (HC) group; (4) did not report whole-brain results (i.e., only ROI results); (5) did not provide sufficient data (e.g., peak coordinates, etc.) even after contacting the authors of the original study. In case the same HC reference group was employed for several subgroup comparisons, only the combined result was included in the meta-analysis.

Meta-analysis

SDM procedures

For each article group, raw statistical maps or coordinates from cluster peaks including their effective sizes (t-values, representing the GMV differences between patients and controls) and sample sizes were entered into the SDM-PSI to be preprocessed using a 20 mm full width half maximum (FWHM) anisotropic Gaussian kernel and 2 mm voxel size. In this step, SDM converts *t*-values into Hedge's *g* effect sizes and their variances using evaluated algorithms (1) in case raw maps for the original study are not available. SDM conducts multiple imputation to estimate the lower and upper bounds of possible effect sizes for each study using an anisotropic Gaussian kernel. Then in the mean analysis, SDM-PSI conducts unbiased maximum likelihood estimation (MLE) of effect sizes and associated standard errors by imputing the effect size maps of individual studies for each group based on MetaNSUE algorithms (2, 3). To prevent a single study or few studies from driving the results, SDM uses a leave one out jackknife procedure. The number of imputations for mean analysis was set to 50 by default. Finally, SDM-PSI allows a Freedman-Lane-based permutation test at the subject level to perform voxel-wise tests of statistical significance while controlling familywise error rate (FWER) using threshold-free cluster enhancement (TFCE) (4). Details of these procedures are provided in the corresponding methodological publications (5, 6) and the SDM-PSI reference manual (<https://www.sdmproject.com/manual/>).

Transdiagnostic meta-analysis

A transdiagnostic meta-analysis of VBM studies across GAD (9 studies, 226 patients), FAD (23 studies, 996 patients) and MDD (46 studies, 2575 patients) was conducted and

thresholded at TFCE-based FWE corrected $p < 0.05$.

Partly resembling the results of a previous transdiagnostic meta-analysis including schizophrenia, bipolar disorder, major depression, substance use disorder and a pooled group of anxiety disorders (7), we observed decreased right insular cortex volume in the overarching pooled meta-analysis (**Figure. S1**). However, the number of MDD studies was at least two times larger than the number of GAD or FAD studies and the imbalance may strongly bias the results in favor of the MDD-related alterations (see also results in the main text demonstrating reduced right mid-insula volumes in MDD but not FAD or GAD, **Figure 2A, B, C**), while the conjunction approach in our main analyses would only identify regions showing convergent alterations across the disorder categories.

Supplement Results

Table S1. Demographic and clinical characteristics of the 9 GAD VBM datasets included in the meta-analysis.

Study	Number (female)		Age (years)		Duration (years)	Medication	Comorbidity	Scanner/ FWHM (mm)	<i>p</i> value	Summary findings
	GAD	HC	GAD	HC						
Chen et al. 2020 *	72 (41)	57 (30)	39.04	40.91	4.56	Medication load index: 1.67 ± 0.69	0	3T/8	<i>p</i> < 0.05 (GRF)	GAD < HC: L/R sgACC/vmPFC, L ITG, R Insula, R dmPFC
Hilbert et al. 2015	19 (16)	24 (17)	33.47	32.25	NA	Drug naïve	12 MDD, 2 dysthymia, 13 other anxiety disorders	3T/8	<i>p</i> < 0.05 (FWE)	GAD > HC: R Striatum

										GAD < HC: R ACC, L
Kim et al.						Medicated			$p < 0.001$	Precuneus, L dlPFC, L
2018	16 (6)	16 (6)	33.00	32.50	5.60	($n = 10$)	NA	3T/6	(uncorr)	OFG, L SOG, L Insula,
										L STG, L mPFC
Liao et al.						Drug naïve			$p < 0.05$ (FWE)	GAD > HC: R
2014	26 (13)	25 (12)	16.85	16.72	NA		0	3T/8		Putamen
										GAD < HC: R
Ma et al.						Drug-free (> 6			$p < 0.05$	Precentral
2019	21 (9)	20 (10)	34.92	35.96	2.39	month)	0	3T/6	(AlphaSim)	gyrus, R SFG
										GAD < HC: R
Makovac et						Medicated ($n = 2$)			$p < 0.05$ (FWE)	Supramarginal
al. 2016	19 (16)	19 (16)	30.00	29.20	16.78		0	1.5T/8		gyrus/postcentral
										gyrus, L Postcentral
										gyrus, R Precentral

										gyrus, L Supramarginal gyrus
										GAD < HC: L
Moon et al. 2014	22 (9)	22 (9)	37.00	33.40	4.90	NA	NA	3T/8	$p < 0.001$ (uncorr)	Midbrain, L Thalamus, L Hippocampus, L Insula, L STG
Schienze et al., 2011	16 (16)	15 (15)	22.90	23.70	3.10	Drug naïve	0	3T/12	$p < 0.05$ (FWE)	--
Strawn et al., 2013	15 (8)	28 (17)	13.00	13.00	NA	Drug naïve	6 ADHD, 6 other anxiety disorders	4T/8	$p < 0.001$ (uncorr)	GAD > HC: R precentral gyrus, R Precuneus; GAD < HC: R PCC, L OFG

Abbreviations: ACC, anterior cingulate cortex; dlPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; FWE, family-wise error; FWHM, full width at half maximum; GAD, generalized anxiety disorder; GRF, Gaussian random field; HC, healthy controls; ITG, inferior temporal gyrus; L, left hemisphere; mPFC, medial prefrontal cortex; NA, not available; OFG, orbitofrontal gyrus; PCC, posterior cingulate cortex; R right hemisphere; SFG, superior frontal gyrus; sgACC, subgenual anterior cingulate cortex; SOG, superior occipital gyrus; STG, superior temporal gyrus; uncorr, uncorrected; VBM, voxel-based morphometry; vmPFC ventromedial prefrontal cortex.

* Studies that provided original whole-brain *t*-maps.

Table S2. Demographic and clinical characteristics of the 32 FAD VBM datasets included in the meta-analysis.

Study	Disorder type	Number (female)		Age (years)		Duration (years)	Medication	Comorbidity	Scanner/ FWHM (mm)	<i>p</i> value	Summary findings
		Patients	HC	Patients	HC						
Bas-Hoogendam et al. 2017 *	SAD	174 (102)	213 (106)	30.60	32.40	15.80	Medicated (n = 24)	8 MDD, 2	3T/7.5 mm	<i>p</i> < 0.05 (FWE)	--
								MDD + PD, 10 GAD, 3 GAD + SP, 2 GAD + PD, 3PD, 6 SP, 26 unknown			
Cheng et al. 2015	SAD	20 (7)	30 (9)	23.30	26.20	3.99	Drug naïve	0	3T/8 mm	<i>p</i> < 0.05 (FWE)	--
Frick et al. 2014	SAD	48 (24)	29 (16)	33.80	23.70	NA	Drug naïve	10 GAD; 7 SP; 3 MDD; 2 PD	NA/8 mm	<i>p</i> < 0.05 (corr)	SAD > HC: L/R Lingual gyrus, L

Author	Year	Group	N (M)	N (M)	Mean	Mean	SD	Medication	Diagnosis	Thickness	p-value	Findings
Irle et al.	2014	SAD	67 (35)	64 (31)	31.00	32.00	15.00	Medicated (n = 6)	16 MDD; 7 SP; 5 PD; 1 GAD	3T/8 mm	$p < 0.001$ (uncorr)	FFG, R Secondary occipital cortex
Kawaguchi et al.	2016	SAD	13 (8)	18 (0)	36.20	33.80	23.30	NA	4 MDD; 1 PD	3T/8 mm	$p < 0.05$ (FWE)	--
Liao et al.	2011	SAD	18 (6)	18 (5)	22.70	21.90	4.10	Drug naïve	0	3T/8 mm	$p < 0.05$ (AlphaSim)	SAD > HC: R mPFC; SAD < HC: L PHG, R ITG
Meng et al.	2013	SAD	20 (6)	19 (6)	21.80	21.60	4.21	Drug naïve	0	3T/12 mm	$p < 0.05$ (AlphaSim)	SAD < HC: L/R Thalamus, R

p < SAD < HC: L/R

0.001 Putamen, L/R OFC,

(FDR) L/R Thalamus

PD < HC: L/R

dmPFC, R vmPFC,

R Amygdala, R

ACC, L/R STG,

p < 0.05 L/R Insula, L/R

(FDR) Lateral

occipitotemporal

gyrus, L cerebellar

vermis

Zhao et al.
2017

SAD

24 (9)

41 (15)

24.50

27.10

7.60

Drug naïve

0

3T/8 mm

0.001

Putamen, L/R OFC,

L/R Thalamus

PD < HC: L/R

dmPFC, R vmPFC,

R Amygdala, R

ACC, L/R STG,

L/R Insula, L/R

Lateral

occipitotemporal

gyrus, L cerebellar

vermis

Asami et al.
2009

PD

24 (15)

24 (15)

37.03

37.01

3.90

Medicated
(n = 36)

13 AG, 3

MDD, 1

dysthymia

1.5T/12 mm

p < 0.05

(FDR)

ACC, L/R STG,

L/R Insula, L/R

Lateral

occipitotemporal

gyrus, L cerebellar

vermis

Kunas et al. 2020	PD	143 (89)	178 (101)	33.65	31.63	NA	Drug naïve	51 MDD	3T/8 mm	$p < 0.001$ (uncorr)	PD < HC: L MTG
Lai & Wu, 2012	PD	30 (19)	21 (11)	47.03	41.14	NA	Drug naïve	13 AG	3T/7.5 mm	$p < 0.005$ (FWE)	PD < HC: L OFC, L IFG, R Insula, L STG
Lai & Wu, 2015	PD	53 (28)	54 (29)	43.28	40.38	5.35	Drug naïve	0	3T/7.5 mm	$p < 0.05$ (FWE)	PD < HC: R IFG R Insula
Massana et al. 2003	PD	18 (11)	18 (10)	36.80	36.70	NA	Drug naïve	15 AG	1.5T/12 mm	$p < 0.05$ (corr)	PD < HC: L PHG
Na et al. 2013	PD	22 (9)	22 (11)	40.18	40.18	NA	Drug naïve	12 AG	3T/8 mm	$p < 0.05$ (FWE)	PD < HC: L/R SOG, cuneus
Protopopescu et al. 2006	PD	10 (6)	23 (11)	33.50	28.70	NA	Medicated (n = 1)	2 AG	3T/12 mm	$p < 0.05$ (GRF)	PD > HC: Brainstem

Sobanski et al. 2010	PD	17 (9)	17 (9)	34.90	33.10	7.90	NA	16 AG, 1 SAD, 1 GAD, 2 AD, 2 PPD	1.5T/12 mm	$p < 0.05$ (FWE)	PD < HC: R MTG, R OFC PD > HC: L/R Cuneus, lingual; PD
Talati et al. 2013	PD	16 (13)	20 (9)	31.80	31.40	13.40	Medicated (n = 9)	GAD,5 SP, 2 OCD,4 DUD,4 AUD	1.5T/8 mm	$p < 0.05$ (corr)	< HC: R precentral, postcentral, R middle cingulate PD > HC: L Insula
Uchida et al. 2008	PD	19 (16)	20 (16)	37.05	36.45	8.34	Medicated (n = 15)	14 AG, 3 MDD, 2 dysthymia	1.5T/12 mm	$p <$ 0.001 (uncorr)	and STG, L Midbrain and pons; PD < HC: R ACC

											PD < HC: L/R
Yoo et al. 2005	PD	18 (9)	18 (7)	33.30	32.00	3.60	Medicated (n = 10)	0	3T/8 mm	$p < 0.05$ (corr)	Putamen, R Precuneus gyrus, R ITG, L STG, L SFG Specific phobia > HC: R ACC, R
Hilbert et al. 2015	SP	59 (45)	37 (28)	23.95	22.76	NA	Drug naïve	0	1.5T/12 mm	$p < 0.05$ (FWE)	Calcarine sulcus, R FFG, L medial OFC, L Precuneus, R Vermis
Schienlei et al. 2013	SP	45 (25)	41 (23)	30.39	29.24	16.69	Drug naïve	0	3T/8 mm	$p <$ 0.001 (uncorr)	--

Abbreviations: ACC, anterior cingulate cortex; AD, adjustment disorder with mixed disturbance of emotions and conduct; AG, agoraphobia; AUD, alcohol use disorder; corr, corrected; dlPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; DUD, drug use disorder; FAD, fear-related anxiety disorder; FDR, false discovery rate; FFG, fusiform gyrus; FWE, family-wise error; FWHM, full width at half maximum; GRF, Gaussian random field; HC, healthy controls; IFG, inferior frontal gyrus; IOG, inferior occipital gyrus; IPL, inferior parietal lobule; ITG, inferior temporal gyrus; L, left hemisphere; LOC, lateral occipital cortex; MCC, medial cingulate cortex ; MDD, major depressive disorder; MFG, medial frontal gyrus; MOG, middle occipital gyrus; mPFC, medial prefrontal cortex; MTG, middle temporal gyrus; NA, not available; OCD, obsessive-compulsive disorder; OFC, orbitofrontal cortex; PCC, posterior cingulate cortex; PCG, paracingulate gyrus; PD, panic disorder; PHG, parahippocampal gyrus; PPD, paranoid personality disorder; PTSD, post-traumatic stress disorder; R right hemisphere; SAD, social anxiety disorder; SFG, superior frontal gyrus; SMA, supplementary motor area; SOG, superior occipital gyrus; SP, specific phobia; STG, superior temporal gyrus; TOFC, temporal-occipital fusiform cortex; uncorr, uncorrected; VBM, voxel-based morphometry; vmPFC ventromedial prefrontal cortex.

* Studies that provided original whole-brain *t*-maps.

Table S3. Demographic and clinical characteristics of the 46 MDD VBM datasets included in the meta-analysis.

Study	Number (female)		Age (years)		Duration (years)	Medication	Comorbidity	Scanner/ FWHM	<i>p</i> value	Summary findings
	MDD	HC	MDD	HC				(mm)		
Abe et al. 2010	21 (10)	42 (20)	48.10	48.00	6.00	Medicated (n = 19)	0	1.5T/6 mm	<i>p</i> < 0.05 (FDR)	MDD < HC: R PHG, L/R Middle frontal gyrus, L IOG, L SMA, R STG, L Parietal lobe, L/R ACC MDD > HC: L Postcentral gyrus, R Postcentral gyrus, L/R
Ahn et al. 2016	34 (29)	26 (19)	32.43	31.40	NA	NA	NA	3T/8 mm	<i>p</i> < 0.05 (AlphaSim)	Parieto-occipital cortex, L/R Putamen, R Thalamus, L/R Hippocampus, L/R Cerebellum;

Author	Year	N	Age (M)	Age (SD)	Age (IQR)	Group	Medication	Scan Type	Resolution	Significance	Regions
Amico et al.	2011	33 (14)	64 (28)	32.00	30.40	3.40	Medicated (n = 27)	0	1.5T/8 mm	$p < 0.05$ (FWE)	MDD < HC: L/R OFC, R dmPFC, R dorsal ACC, L/R MOG, L Cuneus
Arnone et al.	2013	39 (27)	66 (46)	36.30	32.10	14.30	Drug naïve	0	1.5T/8 mm	$p < 0.05$ (FWE)	MDD < HC: L/R Hippocampus/PHG, L/R FFG/ITG, L/R Ventral striatum
Bergouignan et al.	2009	20 (17)	21 (14)	33.16	28.21	8.45	Medicated (n = 20)	0	1.5T/8 mm	$p < 0.05$ (FDR)	MDD < HC: R Cingulate gyrus, R MTG, R Posterior lobe, R SPL, R PHG, L Inferior semi-lunar lobule

Biedermann et al., 2015	46 (34)	35 (22)	50.80	46.40	NA	Medicated (n = 24)	NA	1.5T/8 mm	$p < 0.05$ (FWE)	--
Cai et al., 2015	23 (10)	23 (10)	30.00	30.00	4.35	NA	0	3T/8 mm	$p < 0.001$ (uncorr)	MDD < HC: IFG
Chaney et al. 2014	37 (21)	46 (28)	40.22	36.61	9.65	Medicated (n = 24)	0	3T/10 mm	$p < 0.05$ (FWE)	--
Chen et al. 2016 *	27 (14)	28 (14)	33.00	33.00	6.58	Drug naïve	0	3T/6 mm	$p < 0.05$ (AlphaSim)	MDD > HC: R Postcentral gyrus
Chen et al. 2020	22 (18)	22 (18)	28.70	27.40	4.40	Medicated (n = 17)	0	3T/8 mm	$p < 0.001$ (uncorr)	MDD < HC: R Occipital fusiform gyrus, L Postcentral gyrus
Dannlowski et al. 2015	171 (105)	512 (289)	38.60	33.30	NA	Medicated (n = 171)	0	3T/8 mm	$p < 0.001$ (Monte Carlo)	MDD < HC: R PHG/HC/amygdala, R Insula/putamen, IFG, L

										Lingual gyrus, FFG, Cerebellum, IOG, L/R MCC, L STG/MTG, L/R Thalamus
Fang et al. 2015	20 (8)	18 (8)	59.20	59.10	3.60	NA	NA	1.5T/8 mm	$p < 0.05$ (corrected)	MDD < HC: L/R ITG, L IFG, L Precuneus, R MCC, R FFG, R Cuneus
Förster et al. 2020	63 (33)	46 (22)	42.43	45.35	NA	NA	19 anxiety disorders	3T/8 mm	$p < 0.05$ (FWE)	--
Grieve et al. 2013	102 (54)	34 (16)	33.80	31.50	11.30	NA	0	3T/8 mm	$p < 0.05$ (FDR)	MDD < HC: R Rectal gyrus, R IFG, L FFG, R ITG, L MTG,
Hagan et al. 2015	109 (81)	36 (26)	15.56	15.65	NA	Medicated (n = 37)	0	3T/7 mm	$p < 0.05$ (FWE)	--
Inkster et al. 2011	145 (94)	183 (110)	49.45	48.00	14.30	NA	0	1.5T/10 mm	$p < 0.05$ (FWE)	MDD < HC: R SPL

Kandilarova et al. 2019	39 (29)	42 (29)	47.70	42.60	10.80	Medicated (n = 37)	0	3T/8 mm	$p < 0.05$ (FDR)	MDD < HC: L MFG/ACC
Klauser et al. 2015	56 (40)	33 (21)	34.02	34.71	10.29	Medicated (n = 33)	0	1.5T/10 mm	$p < 0.05$ (permutation)	MDD < HC: L/R vmPFC MDD < HC: L/R Midbrain, L/R sgACC, L/R Thalamus, L Short insular gyrus, L/R
Lee et al. 2011	47 (42)	51 (45)	46.00	45.70	3.89	Medicated (n = 27)	0	1.5T/10 mm	$p < 0.05$ (FDR)	Nucleus accumbens, L/R Amygdala, L/R Hippocampus, L/R FFG, L Lingual gyrus, L/R MTG, R STG, L/R Cerebellum

										MDD < HC: L/R Middle frontal gyrus, L/R Rectal gyrus, L/R Short and long insula gyrus, L/R ACC, MCC,
Lee et al. 2020	20 (20)	21 (21)	42.50	42.30	9.50	Medicated (n = 20)	0	1.5T/10 mm	$p < 0.05$ (FDR)	L/R PCC, L/R Thalamus, L/R Hypothalamus, L/R Amygdala, L/R Hippocampus, L/R PHG, L Lingual gyrus, L/R STG, MTG, ITG MDD < HC: R ACC, R STG,
Leung et al. 2009	17 (17)	17 (17)	45.50	45.80	7.00	Medicated (n = 17)	NA	1.5T/12 mm	$p < 0.001$ (uncorr)	R SFG, L/R MFG, R FFG, R IFG, L/R Precentral gyrus, L MCC, L Insula, L Angular

										gyrus, L Precuneus, L MTG, L MCC, PCC MDD > HC: L L Caudate, R ITG, L Cerebellum, L Lingual
Lu et al. 2018	76 (44)	86 (43)	34.27	33.35	3.74	Drug naïve	0	3T/8 mm	$p < 0.05$ (GRF)	gyrus; MDD < HC: L/R PHG/Hippocampus, R MTG
Lu et al. 2019	30 (13)	48 (30)	23.98	21.50	2.56	Drug naïve	0	3T/8 mm	$p < 0.05$ (GRF)	MDD > HC: R MOG; MDD < HC: L SPL MDD < HC: R ACC, R SMA,
Mak et al. 2009	17 (17)	17 (17)	45.50	45.80	NA	Medicated (n = 17)	0	1.5T/8 mm	$p < 0.001$ (uncorr)	R Precentral gyrus, R Temporal pole, L Angular gyrus, L Precuneus

Modinos et al. 2014	23 (20)	46 (14)	44.60	25.30	NA	NA	NA	1.5T/8 mm	$p < 0.05$ (FWE)	MDD < HC: L/R Orbital gyrus, R MFG, L ACC, L/R IPL, R MTG, L MFG
Nakano et al. 2014	36 (22)	54 (27)	49.00	45.40	5.56	Medicated (n = 31)	0	1.5T/8 mm	$p < 0.05$ (FWE)	MDD < HC: R mPFC, R superior OFC
Opel et al. 2019	506 (308)	358 (178)	49.14	52.57	6.73	Medicated (n = 441)	Comorbidity index: $1.65 \pm$ 0.81	3T/8 mm	$p < 0.05$ (FWE)	MDD < HC: R Insula/STG/MTG, L SFG/MFG, R MFG/IFG
Pannekoek et al. 2014	26 (23)	26 (23)	15.40	14.70	NA	Drug naïve	18 anxiety disorder; 5 ADHD	3T/7 mm	$p < 0.05$ (permutation)	--
Qiu et al. 2016	12 (8)	15 (10)	34.40	33.70	NA	Drug naïve	0	3T/8 mm	$p < 0.001$ (uncorr)	MDD < HC: R Cingulate gyrus

										MDD < HC: L/R
										Hippocampus, FFG, Lingual
										gyrus, L Supramarginal gyrus,
Redlich et al.						Medicated	35 anxiety		$p < 0.05$	IPL, L/R MCC, ACC, mPFC,
2014	58 (36)	58 (37)	37.60	37.70	10.98	(n = 52)	disorder	3T/8 mm	(AlphaSim)	SMA, R Middle frontal gyrus,
										SFG, L/R Precunues, L
										MTG/STG, L Caudate
Redlich et al.						Medicated				
2018	20 (15)	21 (12)	16.00	16.57	2.63	(n = 8)	0	3T/6 mm	$p < 0.05$ (FWE)	--
							2 AUD; 2			
Rodríguez-							AG; 1 AD; 1			
Cano et al.						Medicated	anxiety	1.5T/4 mm	$p < 0.05$ (FWE)	MDD < HC: L FFG
2014	32 (20)	64 (38)	48.68	46.03	10.94	(n = 28)	disorder; 1			
							dysthymia			

Salvadore et al. 2011	58 (37)	107 (60)	38.80	36.20	18.40	Medicated (n = 44)	0	3T/11 mm	$p < 0.05$ (FWE)	MDD < HC: L/R SFG, L MFG MDD > HC: R Cerebellum, R Rolandic operculum, R SFG, R Precuneus, L IFG, R Amygdala;
Scheuerecker et al. 2010	13 (3)	15 (5)	37.90	35.50	4.36	Drug naïve	0	3T/8 mm	$p < 0.001$ (uncorr)	MDD < HC: L IFG, L Inferior frontal operculum, L MTG, R Postcentral gyrus, L IPL, L STG, L Postcentral gyrus, L Rolandic operculum, R IOG, L IFG, ITG

Shad et al. 2012	22 (10)	22 (11)	15.00	16.00	NA	Medicated (n = 4)	2 anxiety disorder; 3 ADHD	1.5T/8 mm	$p < 0.05$ (FWE)	MDD < HC: R IFG, L/R MFG, R SFG, L/R Caudate, R STG, L Thalamus, L/R Cerebellum
Sprengelmeyer et al. 2011	17 (9)	21 (12)	45.60	42.00	NA	Medicated (n = 17)	0	1.5T/8 mm	$p < 0.05$ (Monte Carlo)	MDD < HC: L Insula, R PHG, L MTG, R SFG, L FFG, R Amygdala
Stratmann et al 2014	132 (76)	132 (74)	37.86	37.82	7.78	Medicated (n = 126)	41 anxiety disorder	3T/8 mm	$p < 0.05$ (AlphaSim)	MDD < HC: R Insula, L SPL, L/R STG, L PHG
Straub et al. 2019	60 (48)	43 (38)	17.30	17.62	NA	Medicated (n = 20)	18 unspecified	3T/6 mm	$p < 0.05$ (FWE)	MDD > HC: R dlPFC
Treadway et al. 2009	19 (10)	19 (10)	35.20	30.30	12.90	NA	7 anxiety disorder	3T/12 mm	$p < 0.05$ (FWE)	--
Ueda et al. 2016	30 (13)	48 (13)	44.30	41.20	NA	NA	0	3T/8 mm	$p < 0.05$ (FWE)	MDD < HC: STG

										MDD < HC: L/R Nucleus caudatus, R IFG, R Subgenual
Wagner et al. 2011	30 (25)	30 (25)	37.55	35.10	5.59	NA	0	1.5T/12 mm	$p < 0.05$ (FWE)	cortex, L/R Hippocampus/amygdala, L OFC, L SFG
Wehry et al. 2015	14 (11)	41 (27)	14.00	13.00	NA	NA	5 ADHD; 1 disruptive behavior	4T/8 mm	$p < 0.001$ (uncorr)	MDD > HC: R MFG, L Precuneus, R Thalamus, R Caudate
Yang et al. 2017	35 (35)	23 (23)	44.54	39.09	2.68	Drug naïve	NA	3T/8 mm	$p < 0.005$ (AlphaSim)	MDD < HC: L/R MFG, L/R Insula, L/R Putamen, R Amygdala, R PHG, L Lingual gyrus, Cerebellum
Yüksel et al. 2018	37 (20)	54 (21)	37.90	35.90	NA	Medicated (n = 28)	13 OCD, somatoform	3T/NA	$p < 0.05$ (FWE)	--

or
 personality
 disorder

Zhao et al. 2017	37 (12)	41 (15)	26.70	27.10	2.00	Drug naïve	0	3T/10 mm	$p < 0.001$ (FDR)	MDD > HC: R Temporal pole; MDD < HC: L/R OFC, L/R Putamen, L/R Thalamus, L/R MFG, L Cuneus
Zhou et al. 2018	144 (84)	111 (58)	28.17	27.63	NA	Drug naïve	0	3T/8 mm	$p < 0.05$ (AlphaSim)	MDD < HC: R SOG

Abbreviations: ACC, anterior cingulate cortex; AD, adjustment disorder with mixed disturbance of emotions and conduct; ADHD, attention deficit hyperactivity disorder; AG, agoraphobia; AUD, alcohol use disorder; corr, corrected; dlPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; FDR, false discovery rate; FFG, fusiform gyrus; FWE, family-wise error; FWHM, full width at half maximum; GRF, Gaussian random field; HC, healthy controls; IFG, inferior frontal gyrus; IOG, inferior occipital gyrus; IPL, inferior parietal lobule; ITG, inferior temporal gyrus; L, left hemisphere; MCC, medial cingulate cortex; MDD, major depressive disorder; MFG, medial frontal gyrus; MOG, middle occipital gyrus; mPFC, medial prefrontal cortex; MTG, middle temporal gyrus; NA, not available; OCD, obsessive-compulsive disorder; OFC, orbitofrontal cortex; PCC, posterior cingulate

cortex; PHG, parahippocampal gyrus; R, right hemisphere; SFG, superior frontal gyrus; sgACC, subgenual anterior cingulate cortex; SMA, supplementary motor area; SOG, superior occipital gyrus; SPL, superior parietal lobule; STG, superior temporal gyrus; uncorr, uncorrected; VBM, voxel-based morphometry; vmPFC ventromedial prefrontal cortex.

* Studies that provided original whole-brain *t*-maps.

Table S4. Whole-brain meta-analysis results for VBM studies in GAD, FAD and MDD at $p < 0.0025$, uncorrected.

MNI coordinates	SDM Z-Score	P value	Voxels	Regions	BA	Egger's bias	Egger's p value
GAD > HC							
4, -28, 62	3.411	0.00032	18	R paracentral lobule	4	-0.37	0.832
GAD < HC							
				L insula, rolandic operculum, heschl gyrus, STG, supramarginal gyrus			
-44, -8, 8	-3.951	0.000039	411		48	0.45	0.806
				L IFG, temporal pole, insula			
-32, 24, -10	-3.973	0.000035	247		38/47	-0.41	0.809
				L thalamus	--	0.26	0.878
				R lingual gyrus	17	0.77	0.697
				R IPG	2	0.28	0.873
FAD > HC							
				R lingual gyrus	18	-0.01	0.993
				L lingual gyrus	18	0.05	0.942
SAD > HC							
				L postcentral gyrus, STG			
-56, -20, 22	3.514	0.000220	147		48	0.26	0.797

				R superior longitudinal			
					39/40		
48, -46, 34	3.476	0.000255	91	fasciculus, angular		0.60	0.602
					/48		
				gyrus			
26, -50, 58	3.484	0.000246	66	R SPG	5/7	0.11	0.909
24, 56, 12	3.641	0.000136	57	R SFG, dorsolateral	10	0.05	0.959
				L postcentral/precentral			
-20, -32, 62	3.885	0.000051	35		3	-0.08	0.933
				gyrus			
				R postcentral gyrus,			
56, -26, 48	3.342	0.000416	20		2/3	0.03	0.975
				supramarginal gyrus			
-28, -42, -46	3.574	0.000176	19	L cerebellum,	--	-0.07	0.944
-8, 52, 12	3.380	0.000363	16	L SFG, medial	10	-0.31	0.74
14, -68, -10	3.145	0.000829	11	R lingual gyrus	18	0.15	0.874
-12, -80, -12	3.265	0.000547	11	L lingual gyrus	18	0.56	0.587

PD < HC

38, 0, 8	-3.784	0.000077	63	R Insula	48	-0.79	0.488
48, -2, -10	-3.200	0.000687	12	R STG	48	-0.70	0.494
-36, 10, -22	-3.037	0.001195	12	L temporal pole, STG	38	0.09	0.928

MDD < HC

		0.0000071		R insula, MTG, STG,	48/21		
46, -2, 4	-4.339		877			-0.37	0.405
		53		rolandic operculum	/22		
		0.0000002		L/R SFG, medial	11/10		
2, 36, -10	-5.012		722			-0.54	0.300
		98		orbital, L/R ACG	/32		

		0.0001041					
10, 6, 40	-3.709		118	L/R MCG	32/24	-0.31	0.591
		29					
		0.0009192					
36, -30, -14	-3.115		10	R PHG	20	-0.59	0.371
		23					

Abbreviations: ACG, anterior cingulate/paracingulate gyri; BA, Brodmann area; FAD, fear-related anxiety disorder; GAD, generalized anxiety disorder; HC, healthy controls; IFG, inferior frontal gyrus; IPG, inferior parietal gyri; ITG, inferior temporal gyrus; L, left hemisphere; MCG, median cingulate/paracingulate gyri; MDD, major depressive disorder; MNI, Montreal Neurological Institute; MTG, middle temporal gyrus; PHG, parahippocampal gyrus; R right hemisphere; SDM, seed-based d mapping; SFG, superior frontal gyrus; SPG, superior parietal gyri; STG, superior temporal gyrus; VBM, voxel-based morphometry.




Figure. S1. Brain regions showing decreased GMV of patient vs healthy controls for studies pooled across GAD, FAD and MDD. Clusters were displayed at TFCE based FWE corrected $p < 0.05$.

Supplement References

1. Radua J, Mataix-Cols D, Phillips ML, et al.: A new meta-analytic method for neuroimaging studies that combines reported peak coordinates and statistical parametric maps. *Eur Psychiatry* 2012; 27:605–611
2. Radua J, Schmidt A, Borgwardt S, et al.: Ventral Striatal Activation During Reward Processing in Psychosis: A Neurofunctional Meta-Analysis. *JAMA Psychiatry* 2015; 72:1243–1251
3. Albajes-Eizagirre A, Radua J: What do results from coordinate-based meta-analyses tell us? *Neuroimage* 2018; 176:550–553
4. Smith SM, Nichols TE: Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. *Neuroimage* 2009; 44:83–98
5. Albajes-Eizagirre A, Solanes A, Vieta E, et al.: Voxel-based meta-analysis via permutation of subject images (PSI): Theory and implementation for SDM. *Neuroimage* 2019; 186:174–184
6. Albajes-Eizagirre A, Solanes A, Fullana MA, et al.: Meta-analysis of voxel-based neuroimaging studies using seed-based d mapping with permutation of subject images (Sdm-psi). *J Vis Exp* 2019; 2019
7. Goodkind M, Eickhoff SB, Oathes DJ, et al.: Identification of a common neurobiological substrate for mental illness. *JAMA Psychiatry* 2015; 72:305–315